Substituted bisphenyl butanoic ester derivatives as nep inhibitors

Patent metadata

Field	Value
Publication number	US-2019240177-A1
Application number	US-201916388221-A
Country	US
Kind code	A1
Filing date	Apr 18, 2019
Priority date	Feb 7, 2018
Publication date	Aug 8, 2019
Grant date	—

Abstract

The present disclosure provides a compound of Formula (I);

or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.

First claim

What is claimed is:

1 . A compound of the Formula (I):

wherein:
R 1 is H or (C 1 -C 4 )alkyl;
R 2 is H, (C 1 -C 4 )alkyl, (C 6 -C 10 ) aryl, or 5- or 6-membered heteroaryl comprising 1-3 heteroatoms selected from N, S, and O, wherein the alkyl is optionally substituted with one or more R 3 , and wherein the aryl and heteroaryl are optionally substituted with one or more R 4 ;
each R 3 is independently at each occurrence —NH 2 , (C 1 -C 4 )alkylamino, (C 1 -C 4 )dialkylamino, —OH, —SH, —S(C 1 -C 4 )alkyl, —CO 2 H, —CONH 2 , —NHC(NH)NH 2 , (C 6 -C 10 ) aryl, or 5- to 10-membered monocyclic or bicyclic heteroaryl comprising 1-3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with one or more R 5 ;
each R 4 is independently at each occurrence (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkoxy, halogen, —NH 2 , —OH, or CN; and
each R 5 is independently at each occurrence (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkoxy, halogen, —NH 2 , —OH, or CN;
or a pharmaceutically acceptable salt thereof.

2 . The compound according to claim 1 , having a Formula (II):

or a pharmaceutically acceptable salt thereof.

3 . The compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein R 1 is H, ethyl, or t-butyl.

4 . The compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein R 2 is H or (C 1 -C 4 )alkyl optionally substituted with one to two R 3 .

5 . The compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein R 2 is H or (C 1 -C 4 )alkyl optionally substituted with —NH 2 .

6 . The compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein R 1 is H, ethyl, or t-butyl, and R 2 is H or (C 4 )alkyl optionally substituted with —NH 2 .

7 . The compound of claim 1 selected from:
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-leucine;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-lysine; and
tert-butyl (4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-lysinate;
ethyl (2R,4S)-5-([1,1′-biphenyl]-4-yl)-4-(4-(((S)-1-ethoxy-4-methyl-1-oxopentan-2-yl)amino)-4-oxobutanamido)-2-methylpentanoate;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-arginine;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-histidine;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)glycine;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-alanine;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-valine;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-phenylalanine;
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-tryptophan; and
(4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-isoleucine;
or a pharmaceutically acceptable salt thereof.

8 . The compound of claim 1 , wherein the compound is (4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-leucine or a pharmaceutically acceptable salt thereof.

9 . The compound of claim 1 , wherein the compound is (4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoyl)-L-histidine or a pharmaceutically acceptable salt thereof.

10 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

11 . A combination comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agents.

12 . The combination according to claim 11 , wherein the therapeutically active agents are selected from HMG-Co-A reductase inhibitor, an angiotensin receptor blocker, a calcium channel blocker, an endothelin antagonist, a renin inhibitor, a diuretic, an ApoA-I mimic, an anti-diabetic agent, an obesity-reducing agent, an aldosterone receptor blocker, an endothelin receptor blocker, an aldosterone synthase inhibitor, a CETP inhibitor, and a phosphodiesterase type 5 (PDE5) inhibitor.

13 . The combination of claim 12 , wherein the combination comprises an Angiotensin Receptor Blocker selected from valsartan, candesartan, losartan, irbesartan, telmisartan, olmesartan, eprosartan, fimasartan, and azilsartan, or a pharmaceutically acceptable salt thereof.

14 . A method of inhibiting neutral endopeptidase activity in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

15 . A method of treating a disorder or a disease associated with neutral endopeptidase activity in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

16 . The method according to claim 15 , wherein the disorder or the disease is selected from hypertension, resistant hypertension, pulmonary heart disease, pulmonary hypertension, pulmonary arterial hypertension, isolated systolic hypertension, peripheral vascular disease, heart failure, heart failure with preserved ejection fraction (HF-PEF), heart failure with reduced ejection fraction (HF-REF), mitral stenosis and regurgitation, left ventricular hypertrophy, angina, renal insufficiency, renal failure, diabetic nephropathy, non-diabetic nephropathy, contrast-induced nephropathy, nephrotic syndrome, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, renal vascular hypertension, diabetic retinopathy and end-stage renal disease (ESRD), endothelial dysfunction, diastolic dysfunction, cardiomyopathy, hypertrophic cardiomyopathy, diabetic cardiomyopathy, supraventricular and ventricular arrhythmias, cardiac dysrhythmia, atrial fibrillation (AF), new onset of atrial fibrillation, recurrent atrial fibrillation, cardiac fibrosis, atrial flutter, detrimental vascular remodeling, plaque stabilization, myocardial infarction (MI), renal fibrosis, polycystic kidney disease (PKD), renal failure, cyclical oedema, Meniére's disease, hyperaldosteronism, hypercalciuria, ascites, glaucoma, menstrual disorders, preterm labor, pre-eclampsia, endometriosis, and reproductive disorders, asthma, obstructive sleep apnea, inflammation, leukemia, pain, epilepsy, affective disorders, depression, psychotic condition, obesity, gastrointestinal disorders, wound healing, septic shock, gastric acid secretion dysfunction, hyperreninemia, cystic fibrosis, restenosis, type-2 diabetes, metabolic syndrome, diabetic complications, atherosclerosis, and male and female sexual dysfunction.

17 . The method according to claim 16 , wherein the disorder or the disease is selected from hypertension, pulmonary hypertension, isolated systolic hypertension, resistant hyperten

Assignees

• Novartis Ag

Inventors

• Chai Yongshuai
• Godtfredsen Sven Erik
• Kagan Mark
• Liu Yugang
• Prashad Mahavir
• Wang Zhaoyin
• Zhu Saijie

Classifications

• C07C229/36

  with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K31/41

  having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title

• A61K31/197 Primary

  the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205) · CPC title

• A61K31/405

  Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin · CPC title